Primary contact

Formerly known as Parasol Therapeutics, Visterra is a biotechnology company developing precision antibody-based biological medicines for hard-to-treat diseases using its proprietary Hierotope platform. Its technology is powered by computational tools and techniques, the core of which is Atomic Interaction Network (AIN) analysis, that can identify an area — or epitope — on the target site that is fundamental to its structure and function. This ideal epitope, or hierotope, becomes the target against which the company designs a novel therapeutic to effectively and durably combat the disease. Visterra's lead product candidate, VIS410, is a broad spectrum human monoclonal antibody for the treatment of both seasonal and pandemic influenza. The second product candidate, VIS649, is a monoclonal antibody engineered to treat IgA nephropathy, a rare chronic kidney disease. In addition, Visterra has established a number of partnerships to progress novel antibodies engineered to treat significant diseases with limited treatment options.
Primary contact

Funding 💰

Total $122.1M
Select investors Polaris Partners, Flagship Pioneering, Lux Capital, Bill & Melinda Gates Foundation, Omega Funds, Alexandria Venture Investments, Merck Global Health Innovation Fund, Merck Research Laboratories, Vertex Ventures HC
Last update: May 9, 2018